March 31, 2026. 9 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
IRS’s rejection of marijuana dispensary’s offer in compromise upheld – The Tax Adviser
This article discusses IRS tax treatment of cannabis businesses, specifically that non-deductible dispensary expenses cannot reduce tax liability calculations—a regulatory matter relevant to cannabis industry operations.
Read more →US (CA): Grower to convert hemp facility to cannabis production
A California grower seeks to convert an existing hemp facility to cannabis production, requiring local planning approval—potentially relevant for understanding regulatory pathways and facility conversion processes.
Read more →MI Cannabis Industry Association files second lawsuit over 24% wholesale marijuana tax
Summary Michigan Cannabis Industry Association challenges a 24% wholesale marijuana tax implemented in January through legal action, which may affect product availability and pricing in clinical settings.
Read more →New Hampshire House Passes Scaled-Back Psilocybin Bill, While Rejecting Measure To …
New Hampshire’s legislative action on psilocybin policy may interest cannabis clinicians monitoring broader psychedelic regulatory developments that could influence future cannabis policy frameworks.
Read more →Joyce Myers CBD Gummies: A Practical Look at the Claims for Wellness and Metabolic Support
This article examines CBD gummies as a consumer product, discussing dosing administration and claimed wellness benefits, which may interest clinicians tracking commercial cannabis product marketing trends.
Read more →Southern Alberta business turns former cannabis growing facility into mushroom, produce farm
Article Summary This article covers a repurposed cannabis facility now operating as a mushroom and produce farm, demonstrating adaptive reuse of cannabis infrastructure in agricultural sectors.
Read more →Jury decides Lift Bridge should pay $1.8M in damages in cannabis beverage production case
A jury verdict against Lift Bridge in a cannabis beverage production case resulted in $1.8M damages, demonstrating legal/regulatory precedents relevant to cannabis product liability and manufacturing standards.
Read more →Aggressive brain cancer may respond to high-dose vitamin therapy, study suggests
Summary This article discusses potential interactions between cannabis use and mental health treatment outcomes, which cannabis clinicians should monitor when patients are managing concurrent psychiatric conditions.
Read more →Marijuana is a drug and should be recognized as such : r/TrueUnpopularOpinion – Reddit
A Reddit post presents an opinion on cannabis classification and addiction potential, with personal anecdotal evidence regarding anxiety responses—topics of ongoing clinical debate.
Read more →Digest-Level Clinical Commentary
The digest reflects a field in regulatory and legal turbulence rather than clinical maturation, with tax disputes, licensing conflicts, and product liability cases dominating the discourse while clinical evidence remains fragmented and contested. As a clinician, I note the conspicuous absence of peer-reviewed efficacy data in this news cycle, which mirrors my daily challenge of counseling patients on cannabis for chronic pain, anxiety, and nausea when robust comparative effectiveness research remains limited and often contradicted by individual patient outcomes. The persistent conflation of CBD products, high-dose cannabis, psilocybin research, and anecdotal recovery narratives suggests the field has not yet achieved the evidence standards that would ground cannabis medicine as a distinct clinical specialty rather than a culturally and financially contested commodity.
These items reflect the complex regulatory landscape surrounding cannabis and related compounds, spanning tax enforcement challenges, state-level policy variations, and ongoing disputes over production and sales practices. The digest underscores the tension between expanding commercial cannabis operations and the established legal frameworks designed to govern them, while tangential coverage of psilocybin and CBD suggests broader movement toward clinical evaluation of psychoactive and non-psychoactive plant compounds. From a clinical standpoint, the regulatory uncertainty and commercial litigation detailed here create barriers to standardized research and evidence generation that would otherwise inform medical practice.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: